Tag: DRG stimulation

Abbott has announced that the US Food and Drug Administration (FDA) has approved expanded magnetic resonance imaging (MRI) labelling for its dorsal root ganglion...

SynerFuse has announced that—for the first time in the world, it claims—a solo spine surgeon has performed the SynerFuse procedure in a two-level spinal...

SynerFuse has announced that Michael Park (University of Minnesota, Minneapolis, USA)—principal investigator for the company’s investigational device exemption (IDE) proof-of-concept study—presented data from the study’s...

Justin Zenanko, the CEO of SynerFuse, announced today that—in what the company says is a world-first—a solo spine surgeon has performed the “groundbreaking” SynerFuse...

Intermittent dorsal root ganglion stimulation (DRG-S) has been shown to produce comparable results to continuous stimulation across a two-week period, as reported in Neuromodulation:...

Abbott today announced that it has launched an upgraded version of its NeuroSphere myPath digital health app with enhanced functionality intended to help doctors...

Lower frequencies of dorsal root ganglion stimulation (DRG-S) may be more effective in the treatment of neuropathic pain—as per a late-breaking presentation from Guilherme...

Abbott announced today that UnitedHealthcare (UHC)—the largest private health insurance company in the USA—has updated its ‘Implanted electrical stimulator for spinal cord’ medical policy...

SynerFuse has announced the first implantation in the company's proof-of-concept study evaluating the safety and tolerability of simultaneously implanting spinal fusion hardware and a dorsal...

Bilateral L4 dorsal root ganglion (DRG) stimulation has been shown to evoke strong and reproducible motor responses in the upper leg in patients with...

Dorsal root ganglion (DRG) stimulation is a safe and effective therapy for multiple chronic pain disorders, concludes a pooled analysis published in Neuromodulation. The...

In 2018, the International Neuromodulation Society (INS) project on Consensus Conferences published “The Neuromodulation Appropriateness Consensus Committee on Best Practices for Dorsal Root Ganglion...

Abbott has announced the launch of the new dorsal root ganglion (DRG) Invisible Trial System, which is approved by the US Food and Drug...

The real-world data collected in the PREDICT study has added to the evidence in favour of dorsal root ganglion (DRG) stimulation for the management...

Abbott has announced the European launch of the new Proclaim DRG Neurostimulation System, designed to deliver dorsal root ganglion (DRG) stimulation to patients suffering...

New data published in the January edition of Pain has confirmed the superiority of dorsal root ganglion (DRG) stimulation therapy (from Abbott) over traditional...

Southeast Pain Care is one of the first facilities in North Carolina, USA, to use a new neurostimulation device designed to relieve the sensation...

St Jude Medical has announced the US launch and first post-approval implants of the St Jude Medical Axium Neurostimulator System for dorsal root ganglion (DRG) stimulation...

With a series of acquisitions and recent product approvals, St. Jude Medical has further solidified its place as a leading provider of treatment options...

Now complete, the acquisition of Spinal Modulation adds DRG stimulation technology to the St Jude Medical chronic pain portfolio.

Following the completion of this acquisition, St Jude Medical will become the only medical device manufacturer to offer radiofrequency ablation (RFA), spinal cord stimulation (SCS) and dorsal root ganglion (DRG) stimulation therapy solutions for the treatment of chronic pain.